RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260

Benzinga Newsdesk www.benzinga.com Positive 86.1%

Neg 0% Neu 0% Pos 86.1%

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.